@thenasheffect
🇮🇳Account based in
About this account
- Account based in
- India
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
@StephensonCC 🫁 Thoracic Onc/ Phase1. Asst Director Early Phase; Sr Director AI & Data Science @JCOPO_ASCO podcast host #FromKashmir ● #SpaceAndMedicine 👨🚀
Oklahoma City, OK
Joined September 2018
- Tweets3.5K
- Following1.9K
- Followers2.8K
- Likes22.6K
Nicely done ! Best wishes on your nomination @GevTamamyan !
One of the saddest things to come across today. @rachnatshroff was such a delight even though I have only met her briefly at random meetings. May God have mercy on her soul and give strength to her family :(
Devastating news 💔
Rest in peace dear Rachna.
medicine.arizona.edu/news/20…
Rafeh Naqash, MD, FASCO retweeted
I can’t think of a better testimonial that points to the need for @theNCI trials via groups like @SWOG than this! @LauraEsfeller we are so lucky to have a dedicated & passionate patient advocate in our corner. Appreciate all that you do! @SupportingSWOG
Honored to serve our incredible @SWOG #GUonc committee w/ my fellow patient advocates, Darrell & Joël. It’s empowering to use our lived experience to help create clinical trials for our fellow patients. Years ago, it was @PeggyZuckerman who was my voice when #PAPMET S1500 was created. I’m humbly grateful that brilliant study team led by @montypal not only saved my life with this research, but that it led to a CR that allows me to give back. Thank you to @SupportingSWOG for making it possible for patients to participate in research advocacy!
Rafeh Naqash, MD, FASCO retweeted
This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18 F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC. It offers valuable insights for personalized clinical decision making and supports precision oncology.
Read the full article. bit.ly/4y5Nq5p
#NSCLC
Congratulations @montypal ! Well deserved and more importantly the contribution and impact of what you do is far beyond these awards ! @NazliDizman @ziremozay @ZeynepZengin @neerajaiims @AminNassarMD @PGrivasMDPhD
🌟 Congratulations @montypal who will receive the KCA's Eugene P. Schonfeld Award at #IKCSNA26 in November! We're proud to recognize Dr. Pal's excellence in #kidneycancer oncology and care. Read more: kidneycancer.org/2026-ikcsna…
Surprise indeed.
Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…
Give this a listen !
JCO PO Editor-in-Chief Emeritus Dr. James Ford and @ASCO TAPUR Study Founding PI Dr. Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study and its relationship with the journal. Host Dr. Rafeh Naqash and guests discuss the inception/history of the TAPUR Study, its future, and advances in precision medicine over the past decade.
Listen to the podcast. bit.ly/4yPsiRQ
Excited to see @Falah_Fayaz trajectory who’s been working with me @OUCollegeofMed for a year now applying for match27. Falah is a valedictorian from @GMCSrinagar , has worked on clinical and translational projects including on ADC Tox . ⭐️ candidate for any program ! @Ayeshaaijaz
Submitted my ERAS application! #Match2027 🩺
From Kashmir to the States, this journey has been exciting! It's been a privilege to be able to pursue my passion for research at @StephensonCC working on immunotherapy toxicity and precision oncology.
Grateful to @thenasheffect for his mentorship, and to the amazing people I've been fortunate to work with, @Ayeshaaijaz and @HMAbushukhair
Excited for the next chapter!
#MedTwitter #IMG
AAMC ID: 16736659
Rafeh Naqash, MD, FASCO retweeted
Three lung cancer phase 3 trials selected for presidential sessions at #ESMO26 ! I have been honoured to chair the metastatic lung track this year w 2 proffered paper & 2 rapid oral sessions & even more phase 3 trial results in EGFR lung cancer, radiation, & IO! #lcsm @myESMO
1/4
🔥 #ESMO26
Lung Cancer Presidential Highlights
🇪🇸 Madrid | October 24–25, 2026
Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms:
🎙️ LBA3 | DeLLphi-305
🎙️ LBA5 | KRASCENDO 1
🎙️ LBA6 | SAFFRON
Three Phase 3 readouts to watch closely at #ESMO26 👀
@myESMO @OncoAlert @Larvol
WES/ Epigenomics and MRD testing , rapidly evolving field in Oncology. Great conversation with experts @VivekSubbiah @Dr_R_Kurzrock @GIcancerDoc @chadinabhan with fantastic Qs from @Jani_Chinmay @PGrivasMDPhD #BGT26.
It’s time to dig deep into NGS and what’s new in liquid biopsy.
@thenasheffect leading a panel to discuss. @VivekSubbiah @Dr_R_Kurzrock @GIcancerDoc
Can’t wait to hear the dialogue. #BGT2026 #HealthcareUnfiltered
@PGrivasMDPhD @BalazsHalmosMD @karima_oualla @drshieldsmd
Rafeh Naqash, MD, FASCO retweeted
Happening soon
#BGT2026
Can’t wait to welcome everyone and learn on precision medicine, genes, targets, and biomarkers across all solid tumors.
A bit worried about @BalazsHalmosMD & @VivekSubbiah talks though.
@drshieldsmd @HosseinBorghaei @GIcancerDoc @BasselElRayesMD
Was great having this @JCOPO_ASCO conversation on the history and path forward with Drs Ford and Shilsky on the @ASCO TAPUR basket study.
A Decade of Data: JCO PO and the TAPUR Study. Please give a listen! ascopubs.org/do/decade-data-… @lungoncdoc
Rafeh Naqash, MD, FASCO retweeted
Electronic health records and messages have a major impact on physician workload - though often invisible and underestimated. Report @JCOOP_ASCO show that every patient EHR messages leads to ~7 internal in-basket messages. Contribution to burnout?
ascopubs.org/doi/10.1200/OP-…
Immunotherapy efficacy in pts with pericardial effusions in met NSCLC. Major retrospective study led by @TalalZarif1 now in @OncJournal @AminNassarMD @sarahaboualaiwi
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study academic.oup.com/oncolo/arti…
Totally agree!
I strongly believe that academic leadership positions should have term limits. While an institution may occasionally benefit from an exceptional long-serving leader, there is also a significant risk in allowing individuals to remain in positions of authority indefinitely, particularly when their leadership is ineffective. Because these positions are relatively secure, the broader faculty, staff, and department can end up bearing the consequences of poor leadership for many years.
A reasonable model would be a six-year term, with the possibility of one additional term following a rigorous review. That review should include an independent external committee as well as a meaningful evaluation of the health, performance, and perspectives of the section or department.
I have seen leaders remain in their positions for 12 years or more and, over time, surround themselves primarily with people who agree with them or are reluctant to challenge their decisions. This can create a culture of “yes” people, discourage independent thinking and constructive dissent, and make meaningful change increasingly difficult. Term limits, combined with a credible review process, would promote accountability, encourage renewal, and help ensure that leadership positions serve the interests of the institution and its people rather than becoming positions of indefinite personal authority.
Hopefully the actual data lives upto the expectations! #MerkModerna Neoantigen vaccine
Maybe an unpopular opinion, but...
If your press release claims a trial succeeded, you should *at a bare minimum* disclose effect size and stats for primary endpoint.
If a puny biotech had issued a data-free PR like this, @adamfeuerstein would've ripped them a new one.
Wonderful read relevant to the current times both for academic and operational leaders !
The future belongs not to centers that choose between prominence and presence, but to those disciplined enough to achieve both. @JCOOP_ASCO
Traveling Faculty Paradox: Aligning Individual Success With Institutional Purpose.
Read the full article. bit.ly/450Uapd
Rafeh Naqash, MD, FASCO retweeted
Get rid of the term "provider" in health care!
The need and steps for action.
@AnnalsofIM
acpjournals.org/doi/10.7326/…
